Early Observations on Effects of Mavacamten on Left Atrial Function in Obstructive Hypertrophic Cardiomyopathy Patients

Wessly, Priscilla; Lazzara, Gina E.; Buergler, John M.; Nagueh, Sherif F.

doi:10.1016/j.jcmg.2023.06.008

Cited by 7 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…104,105 Mavacamten also appears to reduce LA systolic function, and additional longitudinal data are needed to determine if this results in an increased risk for AF development. 106…”

Section: Myosin Inhibitorsmentioning

confidence: 99%

Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy

Rowin,

Link,

Maron

et al. 2023

Circulation

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of patients. AF in HCM historically has been characterized as a decisive disease complication associated with substantial risk for thromboembolic stroke and increased morbidity and mortality. However, there have been many advances in treatment strategy resulting in improved outcomes for this patient group. For example, stroke risk in HCM has been greatly reduced by using systemic oral anticoagulation initiated after the first clinical (symptomatic) AF episode, usually with preference given to direct anticoagulants over warfarin. In contrast, stroke risk scoring systems (such as CHA 2 DS 2 -VASc score) are not informative in HCM given the substantial potential for stroke events in patients with low scores, and therefore should not be used for anticoagulation decisions in this disease. A novel risk score specifically designed for HCM (HCM-AF score) can reliably identify most patients with HCM at risk for future AF. Although a strategy focused on controlling ventricular rate is effective in asymptomatic (or minimally symptomatic) patients with AF, restoring and maintaining sinus rhythm is required for most patients with marked AF symptom burden and impaired quality of life. Several antiarrhythmic drugs such as sotalol, disopyramide, and amiodarone, can be effective in suppressing AF episodes; albeit safe, long-term efficacy is supported by only limited data. Catheter AF ablation has emerged as an important treatment option for some patients, although freedom from AF after a single ablation is relatively low (35% at 3 years), multiple ablations and the concomitant use of antiarrhythmic drugs can control AF with more than two-thirds of patients maintaining sinus rhythm at 5 years. Surgical AF ablation with biatrial Cox-Maze IV performed as an adjunctive procedure during myectomy can reduce symptomatic AF episodes (70% of patients free from AF at 5 years). For the vast majority of patients who have HCM with AF, the implementation of contemporary therapies has allowed for improved quality of life and low HCM-related mortality.

show abstract

“…104,105 Mavacamten also appears to reduce LA systolic function, and additional longitudinal data are needed to determine if this results in an increased risk for AF development. 106…”

Section: Myosin Inhibitorsmentioning

confidence: 99%